Cancer :: Health Canada approves Sativex for cancer pain
GW Pharmaceuticals plc (AIM: GWP) and Bayer Inc., a subsidiary of Bayer AG, announce that Health Canada has approved Sativex?, a cannabis derived pharmaceutical treatment, as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain.